Our client is a small pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing.
They are seeking an Expert consultant; 2 days a week; for the role of Project Director and Head of Development. The position will define and lead project activities for all of the early portfolio projects to be executed via a virtual (fully outsourced) R&D model, to achieve short- and longer-term project goals, with the aim of adding to the company’s value.
The position requires significant experience in the research and development of pharmaceuticals, ideally for orally delivered and inhaled small molecules. A proven ability to lead the development of medicines through the early stages of development is essential, with experience of later stage development also highly desirable. The role requires demonstrated leadership skills and the ability to develop and deliver compelling project strategies to ensure delivery of project milestones on time and within budget. It is highly desirable that the role holder has development experience with inhaled medicines (either novel or generic). In addition, it is preferable if the role holder has a good appreciation of physical chemistry, solid-state forms and the patenting process.
In addition, the role holder is expected to make a contribution to the overall strategy with regards to project priorities and participating in business development discussions with 3rd party pharma companies with a view to out-licensing assets at an early stage in development.
They are ideally looking for someone with significant pharmaceutical industry experience, in drug development for global markets with a successful track record of project leadership in drug development preferably for early development projects (pre-clinical and Phase 1), preferably via an outsourced model; R&D experience in late-stage development is also an advantage. Experience in respiratory/oncology R&D and the development of oral and inhaled small molecule medicines, preferably with experience of the 505(b)(2) regulatory pathway.